We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Immunoassays for Extrapulmonary Tuberculosis Need Improvement

By LabMedica International staff writers
Posted on 26 Aug 2013
The diagnosis of extrapulmonary tuberculosis (EPTB) is challenging as routine methods for diagnosis, such as smear for acid-fast bacilli (AFB) and culture of Mycobacterium tuberculosis on solid media, have poor sensitivity. More...


Nucleic acid amplification test and liquid culture methods are costly and required sophisticated infrastructure and therefore antibody based serodiagnosis tests for tuberculosis (TB) are used widely in developed and developing countries.

Scientists at the All India Institute of Medical Sciences (New Delhi, India) evaluated the diagnostic performance of commercially available enzyme-linked immunosorbent assay (ELISA) kit in the diagnosis of EPTB. They prospectively enrolled 354 patients, of whom 217 (61.2%) were EPTB patients and 137 (38.7%) were subjects with no suggestive TB, between 2007 and 2011. The mean age was 29.7 years for the EPTB patients and 31.2 years for the controls. Before culture inoculation, all samples were examined microscopically after Zeihl-Neelsen stain. All the isolates were confirmed as M. tuberculosis by species-specific in-house multiplex polymerase chain reaction (PCR) and phenotypic methods.

Three immunoglobulin based ELISA kits, PATHOZYME MYCO IgG, IgA, and IgM (Omega Diagnostics Limited; Alva, Scotland, UK) were used to check levels of antimycobacterial antibodies against two antigens in the serum of diseased and controls. The individual and overall sensitivity rates of IgM, IgA, and IgG assays were 29%, 24.4%, and 34.5%, respectively, while their specificities were 70.8%, 77.3%, and 68.6%, respectively. Not all TB patients produce antibodies against all antigenic epitopes in the cell walls of the tubercle bacilli, which infers on the inconsistency in specificity of antibody-based assays among different patient groups like gender, age, ethnicity, and geographical distribution.

The authors concluded that even though the specificity of the Pathozyme Myco IgA, IgM, and IgG was significantly better and acceptable as compared to pulmonary TB, the sensitivity of these kits was less than can be expected, and they did not recommend their use for diagnosis of EPTB. While a negative result by any one of these tests would be useful in helping to exclude disease in a population with a low prevalence of tuberculosis, a positive result may aid in clinical decision making when applied to symptomatic patients being evaluated for active tuberculosis. The study was published on August 1, 2013, in the Journal of Laboratory Physicians.

Related Links:

All India Institute of Medical Sciences
Omega Diagnostics Limited



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.